Five-Year Renewal and Automatic Cancellation of Iraqi Registrations

1. Key takeaways

Registration in Iraq is not a one-off event. According to the Drug Registration Regulations published by the Registration Department of the Technical Affairs Directorate of the Iraqi Ministry of Health, the validity of a registration is five years for pharmaceuticals and ten years for Iraqi domestic products, after which re-registration must be completed at a re-registration fee of USD 100 (that rate appears in the pharmaceutical clauses). Section 6.5 of Iraq Pharmaceutical Country Profile 2020, a publication of the Iraqi Ministry of Health, states further that information on registered medical products, authorized companies and licensed facilities should be recorded, reviewed and updated by the Registration Department every five years, and that any scientific office or pharmaceutical company that fails to submit updated information within five years of registration has its registration cancelled automatically. The former is graded secondary and not citable as a legal provision (the document has no number or date); the latter is graded primary, indirectly verified (the source site was blocked and the content was obtained through indexed snippets).

• Validity clause: five years for pharmaceuticals and ten years for domestic products, per Section A item 4, with re-registration required on expiry.
• Re-registration fee of USD 100 appears in Section E item 27, within the pharmaceutical fee schedule.
• Five-year update duty: the Registration Department records, reviews and updates registered information every five years, per Country Profile 2020 Section 6.5.
• Automatic cancellation: a scientific office or pharmaceutical company failing to send updated information after five years of registration has its registration cancelled automatically.

2. Legal basis

The table below lists the sources cited in this article together with their document numbers, publication dates and the provisions relied upon.

Source grading: the former is graded secondary and must not be cited as a legal provision (hosted at https://pharmexcil.com/uploadfile/ufiles/380351111_drug_regpdf.pdf); the latter is graded primary, indirectly verified — the PDF is hosted on old.moh.gov.iq, an official domain, access was blocked by Cloudflare this round, and the English original of Section 6.5 was obtained through indexed snippets, so the original must be re-checked before formal citation.

Excerpts of the original provisions:

• Section A item 4: the validity of a registration is five years for pharmaceuticals and ten years for domestic products; re-registration is required on expiry.
• Section E item 27: the re-registration fee is USD 100 (alongside item 26, a registration fee of USD 165 per product, both within the pharmaceutical clauses).
• Country Profile 2020 Section 6.5 (English original): «information on registered medical products, authorized companies and licensed facilities should be recorded, reviewed, and updated every five years by the Registration Department. Any scientific bureau or pharmaceutical company fail to send updated information after five years of the registration, their registration will be cancelled (revoked) automatically.»

3. Expert insights

Insight 1 | The five years in the two documents point to two different things. Section A item 4 is a validity clause: expiry requires renewal. Section 6.5 is an information update duty: every five years the registration information must be refreshed, failing which the registration is cancelled. The consequences differ — lapse on expiry without renewal in the former, automatic cancellation for failure to submit updated information in the latter. In internal management these should be two alarms, one for renewal and one for the periodic information submission.

Insight 2 | Cross-border comparison: the five-year cycle is common, but automatic cancellation is Iraq’s hard wording. Chinese device registration certificates are valid for five years, with renewal possible six months before expiry and cancellation generally requiring a procedure; EU CE certificates usually run five years or shorter as set by the notified body; the US FDA 510(k) has no expiry, while establishment listing requires annual renewal fees. Iraq writes failure to update information directly as cancelled automatically: no administrative penalty decision is needed, and a company can lose its standing without knowing, discovering it only when the next import is blocked.

Insight 3 | Debunking: presenting the USD 100 re-registration fee as the device renewal fee is inaccurate. The context of Section E items 26 and 27 is the pharmaceutical registration and re-registration fee schedule; the only explicit amount in Section D, the device part, is the company registration fee of USD 1,000, and no re-registration fee is listed for devices. Device companies should therefore not budget renewal at USD 100. GRZAN’s approach is a practical estimate: reserve at the USD 1,000 order of magnitude and settle per the acceptance notice (no device-specific official provision on the re-registration amount was found).

Insight 4 | The duty holder of automatic cancellation is the scientific office or pharmaceutical company, and the risk passes through to the manufacturer. Section 6.5 places the submission duty on the scientific bureau or the company. If a Chinese manufacturer’s registration sits under a local scientific office and that office fails to update, the Chinese side bears the consequence: its registration standing is cancelled by someone else’s administrative inaction. This is the core risk developed in article 19 of this series.

Insight 5 | The difference in evidentiary grade dictates the wording. The sentence in Section A item 4 has no date and no number and can only be cited as according to the document published by the authorities; Section 6.5 comes from the Ministry of Health’s own publication and is stronger evidence, but only indexed snippets could be obtained this round. In formal opinions, GRZAN lists both side by side with their grades noted, letting the client judge the risk exposure, rather than citing only the more convenient one.

4. Practical recommendations

• Keep a dual-alarm ledger: one entry for the registration approval date plus five years, the validity; one for each information submission date plus five years, the update duty. Both entries have a named owner and do not rely on the local representative’s own discipline.
• Write into the agency agreement with the local scientific office that it must submit the information update annually and return scanned receipts for record, with liability for compensation if cancellation results from non-performance.
• Run an annual standing check: obtain written confirmation of the current status from the registration database or the agent. Practical estimate: the Iraqi side usually gives no separate notice of cancellation (no official provision found).
• Prepare renewal documents as the full initial registration set plus change records: expiry of the manufacturer’s certificate and changes of product name or address must all be stated at once.
• Budget at the USD 1,000 order of magnitude, not USD 100; for the difference, require a written explanation from the Iraqi side before settlement.

5. Verification checklist

• □ Once moh.gov.iq is restored, download the Iraq Pharmaceutical Country Profile 2020 (old.moh.gov.iq/upload/upfile/ar/1375.pdf) and check the English original and section number of Section 6.5 page by page.
• □ Check whether a newer edition exists, such as a 2023 country profile, and confirm whether the five-year update duty still applies.
• □ Check whether the five years and ten years of Section A item 4 and the five years of Section 6.5 have been adjusted by later ministerial instructions.
• □ Request written proof of the company’s current registration status from the Registration Department and confirm no cancellation has occurred.
• □ Check whether the agency agreement contains the clauses on the information update duty, receipt filing and compensation for breach.
• □ Check the current amount for device re-registration and do not carry over the pharmaceutical rate of USD 100.
• □ Re-verify whether the official documents cited in this article have been replaced by subsequent instructions or resolutions (verification baseline date of this article: October 29, 2026).

Regulatory information verified as of October 29, 2026.

How GRZAN can help. GRZAN provides medical device and IVD registration, quality system, authorised representative and local testing support for the Iraqi market. Our team manages federal and Kurdistan registration applications, prepares reference-country dossiers, and supports post-market vigilance obligations. Business enquiries: info@grzanglobal.com